Diligence memo · auto-generated · as of July 3, 2026

Ocucure Therapeutics Inc

Ocucure Therapeutics Inc looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Ocucure Therapeutics Inc operates in Pharmaceuticals, based in ROANOKE.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Ocucure Therapeutics Inc has raised $1.8M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $825K on 2008-09-17.

Most recent recorded round closed around 2017-03-14.

Valuation (modeled)modeled

Provath models Ocucure Therapeutics Inc at approximately $4.7M (range $56K–$54M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.25× the median modeled value of Pre-Seed Pharmaceuticals companies in 2016–2018 (56 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 20 months.

Last raise 9.3 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 26% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 9% of those peers.

Closest niche peers: Essentia Pharma Socal, Llc, Essentia Pharma Florida, Llc, Novellus LLC, Blake Insomnia Therapeutics, Inc., Eleusis Benefit Corporation, PBC.

Peoplefiled

13 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.